-- Evidence of Monotherapy Activity: Partial response observed in a MEK-rechallenge 3rd-line melanoma patient with BRAF V600E mutation who remains on trial for more than 11 months -- -- A second ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback